RenovoRx Inc RNXT.OQ RNXT.O is expected to show a rise in quarterly revenue when it reports results on March 30 for the period ending December 31 2025
The Mountain View California-based company is expected to report a 876.2% increase in revenue to $419.75 thousand from $43 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for RenovoRx Inc is for a loss of 8 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for RenovoRx Inc is $5.50, about 386.7% above its last closing price of $1.13
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.08 | -0.08 | Met | 0 | |
Jun. 30 2025 | -0.09 | -0.08 | -0.08 | Met | 5.9 |
Mar. 31 2025 | -0.08 | -0.08 | -0.08 | Met | 0 |
Dec. 31 2024 | -0.12 | -0.11 | -0.13 | Missed | -18.2 |
Sep. 30 2024 | -0.12 | -0.12 | -0.10 | Beat | 16.7 |
Jun. 30 2024 | -0.10 | -0.10 | -0.10 | Met | 0 |
Mar. 31 2024 | -0.13 | -0.14 | -0.07 | Beat | 51.7 |
Dec. 31 2023 | -0.30 | -0.30 | -0.31 | Missed | -2.2 |
This summary was machine generated March 27 at 21:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments